Intramuscular extended-release naltrexone: Current evidence

Annals of the New York Academy of Sciences

Volumn 1216, Issue 1, 2011, Pages 144-166

  Gastfriend, David R ^a  

^a ALKERMES INC   (United States)

Author keywords

Alcohol dependence; Extended release naltrexone; Naltrexone; Opioid dependence

Indexed keywords

ACAMPROSATE; CAMPREL; DISULFIRAM; MU OPIATE RECEPTOR; NALTREXONE; UNCLASSIFIED DRUG;

ADDICTION; ALCOHOLISM; ARTICLE; DETOXIFICATION; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INTERSTITIAL PNEUMONIA; LOEFFLER PNEUMONIA; OLFACTORY SYSTEM; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; QUALITY OF LIFE; VISUAL FIELD;

EID: 79251524169     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05900.x     Document Type: Article

References (125)

1. Grant, B.F. et al 2004. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend. 74: 223-234.
2. McGinnis, J.M. & W.H. Foege 1999. Mortality and morbidity attributable to use of addictive substances in the United States. Proc. Assoc. Am. Physicians 111: 109-118.
3. Midanik, L.T. et al 1996. Risk functions for alcohol-related problems in a 1988 US national sample. Addiction 91: 1427-1437.
4. Murray, C.J.L. & A.D. Lopez 1996. The global burden of disease. World Health Organization. Harvard University Press, Cambridge, MA
5. Rehm, J. et al 2003. Alcohol-related morbidity and mortality. Alcohol Res. Health 27: 39-51.
6. Room, R., T. Babor & J. Rehm 2005. Alcohol and public health. Lancet 365: 519-530.
7. Adewuya, A.O. et al 2007. Alcohol use disorders among Nigerian University students: prevalence and sociodemographic correlates. Nigeria J. Psychiatry 5: 5-9.
8. Benegal, V. 2005. India: alcohol and public health. Addiction 100: 1051-1056.
9. Uchtenhagen, A. 2004. Substance use problems in developing countries. Bull. World Health Org. 82: 641-642.
10. Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2009. Data on Substance Abuse Treatment Facilities. Rockville MD, US Department of Health and Human Services, DHHS publication SMA 05-4112.
11. National Institute on Alcohol Abuse and Alcoholism. Helping Patients Who Drink Too Much: A Clinician's Guide. 2005 ed. [NIAAA Web site]. Available at: Accessed August 8, 2010.
12. Fuller, R.K. et al 1986. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA. 256: 1449-1455.
13. Wentland, M.P., Lou, R., Lu, Q., et al 2009. Syntheses of novel high affinity ligands for opioid receptors. Bioorg. Med. Chem. Lett. 19: 2289-2294.
14. Wall, M.E., D.R. Brine, & M. Perez-Reyes 1980. The metabolism of naltrexone in man. NIDA Res. Monogr. 28: 105-131.
15. Verebey, K. et al 1976. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin. Pharmacol. Ther. 20: 315-328.
16. Harris, R.A. & C.K. Erickson 1979. Alteration of ethanol effects by opiate antagonists. Curr. Alcohol 5: 17-28.
17. Altshuler, H.L., P.E. Phillips & D.A. Feinhandler 1980. Alteration of ethanol self- administration by naltrexone. Life Sci. 26: 679-688.
18. Volpicelli, J.R. et al 1992. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 49: 876-880.
19. O'Malley, S.S. et al 1992. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch. Gen. Psychiatry 49: 881-887.
20. King, A.C. et al 1997. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology 129: 15-22.
21. Swift, R.M. et al 1994. Naltrexone-induced alterations in human ethanol intoxication. Am. J. Psychiatry 151: 1463-1467.
22. McCaul, M.E. et al 2000. Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects. Neuropsychopharmacology 22: 480-492.
23. Volpicelli, J.R. et al 1995. Effect of naltrexone on alcohol "high" in alcoholics. Am. J. Psychiatry 152: 613-615.
24. Streeton, C. & G. Whelan 2001. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol. 36: 544-552.
25. Kranzler, H.R. & J. Van Kirk 2001. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin. Exp. Res. 25: 1335-1341.
26. Bouza, C. et al 2004. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 99: 811-828.
27. Srisurapanont, M. & J. Ngamwong 2005. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int. J. Neuropsychopharmacol. 8: 267-280.
28. Pettinati, H.M. et al 2006. The status of naltrexone in the treatment of alcohol dependence. J. Clin. Psychopharmacol. 26: 610-625.
29. Swift, R. et al 2007. Adherence monitoring in pharmacotherapy for alcohol dependence: a systematic review of naltrexone clinical trials. Presented at American Society of Addiction Medicine, Miami, FL
30. Volpicelli, J.R. et al 1997. Naltrexone and alcohol dependence. Arch. Gen. Psychiatry 54: 737-742.
31. Chick, J. et al 2000. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 35: 587-593.
32. Gueorguieva, R. et al 2007. New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biol. Psychiatry 61: 1290-1295.
33. DiMatteo, M.R. 2004. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med. Care. 42: 200-209.
34. Hermos, J.A. et al 2004. Patterns of dispensed disulfiram and naltrexone for alcoholism treatment in a veteran patient population. Alcohol Clin. Exp. Res. 28: 1229-1235.
35. Kranzler, H.R. et al 2008. Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization. Addiction 103:1801-1808.
36. Harris, K.M., A. Devries, & K. Dimidjian 2004. Trends in naltrexone use among members of a large private health plan. Psychiatr. Serv. 55: 221.
37. Narcotic antagonists: the search for long-acting preparations. 1976. NIDA Res. Monogr. R. Willette ed. Rockville, MD
38. Renault, P. 1981. Treatment of heroin-dependent persons with antagonists: current status. NIDA Res. Monogr. 28: 11-22.
39. Olsen, J.L. & F.A. Kincl 1981. A review of parenteral sustained-release naltrexone systems. NIDA Res. Monogr. 28: 187-193.
40. Shive, M.S. & J.M. Anderson 1997. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28: 5-24.
41. ® naltrexone, a once a month long-acting injection, for the treatment of alcohol dependence. Frontiers Biosci. 10: 643-655.
42. Johnson, B.A. et al 2004. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (vivitrex) in patients with alcohol dependence. Alcohol Clin. Exp. Res. 28: 1356-1361.
43. Dunbar, J.D. et al 2006. Single and multiple dose pharmacokinetics of long-acting naltrexone. Alcohol Clin. Exp. Res. 30: 480-490.
44. Turncliff, R.Z. et al 2005. Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment. J. Clin. Pharmacol. 45: 1259-1267.
45. Anton, R.F. et al 2006 Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 295: 2075-2076.
46. M. J., Kreek, personal communication.
47. Garbutt, J.C. et al 2005. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 293: 1617-1625.
48. O'Malley, S.S. et al 2007. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J. Clin. Psychopharmacol. 27: 507-512.
49. Drug and Alcohol Services Information System. The DASIS Report: Discharges from Detoxification: 2000. Office of Applied Studies, Substance Abuse and Mental Health Services Administration (SAMHSA). Available at: Accessed August 19, 2007.
50. Gastfriend D.R., Q. Dong, J. Loewy et al. Durability of effect of long-acting injectable naltrexone. Poster presented at the Annual Meeting of the American Psychiatric Association, Atlanta, GA, May 23, 2005.
51. McLellan, A.T. et al 2000. Drug dependence, a chronic medical illness implications for treatment, insurance, and outcomes evaluation. JAMA. 284: 1689-1695.
52. Gastfriend, D.R. 2005. Physician substance abuse and recovery: what does it mean for physicians-and everyone else JAMA. 293: 1513-1515.
53. Alkermes, data on file.
54. Donovan, D. et al 2005. Quality of life as an outcome measure in alcoholism treatment research. J. Stud. Alcohol Suppl. 15: 119-139.
55. Foster, J.H. et al 1999. Quality of Life in alcohol-dependent subjects - a review. Qual. Life Res. 8: 255-261.
56. Pettinati, H.M. et al 2009. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. Alcohol Clin. Exp. Res. 33: 350-356.
57. Ware, J., M. Kosinski, & J. Dewey 2000. How to score version 2 of the SF-36 health survey. Quality Metric Incorporated, Lincoln, RI
58. Donovan, D.M. et al 2006. Concurrent validity of the Alcohol Use Disorders Identification Test (AUDIT) and AUDIT zones in defining levels of severity among out-patients with alcohol dependence in the COMBINE study. Addiction. 101: 1696-1704.
59. Berggren, U. et al 2007. Tobacco use is associated with more severe alcohol dependence, as assessed by the number of DSM-IV criteria, in Swedish male type 1 alcoholics. Alcohol Alcohol. 42: 247-251.
60. Lima, A.F. et al 2005. Association between psychiatric symptoms and severity of alcohol dependence in a sample of Brazilian men. J. Nerv. Ment. Dis. 193: 126-130.
61. Morgan, M.Y., F. Landron & P. Lehert 2004. Improvement in quality of life after treatment for alcohol dependence with acamprosate and psychosocial support. Alcohol Clin. Exp. Res. 28: 64-77.
62. Krystal, J.H. et al 2001. Naltrexone in the treatment of alcohol dependence. N. Engl. J. Med. 345: 1734-1739.
63. Morley, K.C. et al. 2006. Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-center, randomized, double-blind, placebo-controlled trial. Addiction 101: 1451-1462.
64. Baltieri, D.A. et al 2009. The role of alcoholic beverage preference in the severity of alcohol dependence and adherence to the treatment. Alcohol. 43: 185-195.
65. Pettinati, H. et al 2009. The efficacy of extended-release naltrexone based on severity of alcohol dependence. Presented at the Research Society on Alcoholism, San Diego, CA
66. Skinner, H.A. & B.A. Allen 1982. Alcohol dependence syndrome: measurement and validation. J. Abnorm. Psychol. 91: 199-209.
67. Lapham, S. et al 2009. The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients. J. Subst. Abuse Treat. 36: 1-6.
68. Drummond, D.C. & S. Glautier 1994. A controlled trial of cue exposure treatment in alcohol dependence. J. Consult. Clin. Psychol. 62: 809-817.
69. Lukas, S.E. et al 2010. Extended-release injectable naltrexone (XR-NTX) treatment of alcohol dependence: reduction in cue-induced craving and CNS activation on fMRI. Presented at the Research Society on Alcoholism, San Antonio, Texas
70. U.S. Department of Health and Human Services. 2007. Have a safe and sober holiday. Retrieved August 8, 2010, from
71. FDA ALERT Information for healthcare professionals: naltrexone injection site reactions [naltrexone for extended-release injectable suspension (marketed as Vivitrol)]. Available at: Accessed on: 08/12/2008
72. Lucey, M.R. et al 2008. Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics. Alcohol Clin. Exp. Res. 32: 498-504.
73. Pfohl, D.N. et al 1986. Naltrexone hydrochloride (trexan): a review of serum transaminase elevations at high dosage. NIDA Res. Monogr. 67: 66-72.
74. Balldin, J. et al 2003. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin. Exp. Res. 27: 1142-1149.
75. Croop, R.S., E.B. Faulkner & D.F. Labriola 1997. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch. Gen. Psychiatry 54: 1130-1135.
76. Gastpar, M. et al 2002. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J. Clin. Psychopharmacol. 22: 592-598.
77. Kim, S.W. et al 2006. Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients. Clin. Neuropharmacol. 29: 77-79.
78. Verebey, K.G. & S.J. Mule 1986. Naltrexone (trexan): a review of hepatotoxicity issues. NIDA Res. Monogr. 67: 73-81.
79. Yen, M.H. et al 2006. Study of hepatotoxicity of naltrexone in the treatment of alcoholism. Alcohol. 38: 117-120.
80. Alkermes, data on file.
81. Dean, R.L. et al 2008. Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone. Pharmacol. Biochem. Behav. 89: 515-522.
82. Gonzales, R.A. & F. Weiss 1998. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J. Neurosci. 18: 10663-10671.
83. Myrick, H. et al 2008. Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch. Gen. Psychiatry 65: 466-475.
84. Zhang, M., C. Balmadrid & A.E. Kelley 2003. Nucleus accumbens opioid, GABaergic, and dopaminergic modulation of palatable food motivation: contrasting effects revealed by a progressive ratio study in the rat. Behav. Neurosci. 117: 202-211.
85. Tsai, H.W. et al 2006. Monoamine levels in the nucleus accumbens correlate with male sexual behavior in middle-aged rats. Pharmacol. Biochem. Behav. 83: 265-270.
86. Daniel, M., A.D. Martin & J. Carter 1982. Opiate receptor blockade by naltrexone and mood state after acute physical activity. Br. J. Sports Med. 26: 111-115.
87. Kim, S.W. et al 2001. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol. Psychiatry 49: 914-921.
88. Yeomans, M.R. & R.W. Gray 2002. Opioid peptides and the control of human ingestive behaviour. Neurosci. Biobehav. Rev. 26: 713-728.
89. Murphy, M.R. et al 1990. Naloxone inhibits oxytocin release at orgasm in man. J. Clin. Endocrinol. Metab. 71: 1056-1058.
90. Kim, S.W. 1998. Opioid antagonists in the treatment of impulse-control disorders. J. Clin. Psychiatry 59: 159-164.
91. O'Brien, C.P. et al In press. Long-term opioid blockade and hedonic response: preliminary data from two open-label extension studies with extended-release naltrexone. Am. J. Addictions.
92. Abraham, A.J. & P.M. Roman 2010. Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector. J. Stud. Alcohol Drugs 71: 460-466.
93. Lee, J.D. et al 2010. Extended-release naltrexone for treatment of alcohol dependence in primary care. J. Subst. Abuse Treat. 39: 14-21.
94. Publicker, M. 2010. Extended-release injectable naltrexone (XR-NTX) in the alcoholic homeless: initial experience. Presented at SAAS/NIATx, Cincinnatti, OH.
95. Batki, S.L. et al 2007. Long-acting injectable naltrexone versus oral naltrexone in serious mental illness: a pilot feasibility trial. Presented at Research Society on Alcoholism, Chicago, IL.
96. Greenfield, L.A. & M. Henneberg 2001. Victim and offender self-reports of alcohol involvement in crime. Alc. Res. Health 25: 20-31.
97. Lapham, S.C. & G.P. McMillan 2010. Open-label pilot study of extended-release naltrexone to reduce drinking and driving among repeat offenders. J. Addiction Med. Published ahead of print, 28 July.
98. Finigan, M., T. Perkins & P. Zold-Kilbourn 2010. Preliminary evaluation of extended-release naltrexone (XR-NTX) in Michigan and Missouri drug courts. Presented at the American Psychiatric Association, Boston, MA
99. ADAW. 2009. Mo. requires providers to offer medication-assisted treatment. Alcoholism and Drug Abuse Weekly 21: 3.
100. Harwood, H., D. Fountain & G. Livermore 1998. The economic costs of alcohol and drug abuse in the United States 1992. Report prepared for the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Department of Health and Human Services. National Institute of Health Publication no. 98-4327. Rockville, MD Available at: (accessed 9 August, 2010).
101. Mannelli P. et al 2007. Long-acting injectable naltrexone for the treatment of alcohol dependence. Exp. Rev. Neurotherapeutics 7: 1265-1277.
102. Kranzler, H.R., D.R. Wesson, & L. Billot 2004. Naltrexone depot for the treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin. Exp. Res. 28: 1051-1059.
103. Borawala, A.S., P. Gill & S. Jan 2009. Utilization patterns for Vivitrol (naltrexone for extended-release injectable suspension) for alcohol dependence. Presented at the Academy of Managed Care Pharmacy, Orlando, FL
104. Mark, T.L. et al 2010. Characteristics and outcomes of insured patients treated with extended-release naltrexone (XR-NTX) or oral alcohol dependence medications. Presented at the College on Problems of Drug Dependence, Scottsdale, Arizona
105. Un, H. 2008. Utilization and persistence with alcohol dependence pharmacotherapies in a large commercial insurance population, Presented at the SAMHSA/CSAT Invitational Conference on Economic Access to Treatment, Washington, DC
106. Kampman, K. et al 2008. Long-term safety and tolerability of extended-release naltrexone in alcohol and/or opioid-dependent patients: a randomized, active-controlled study. Presented at American Psychiatric Association, Chicago, IL
107. Comer, S.D. et al 2006. Injectable, sustained-release naltrexone for the treatment of opioid dependence. Arch. Gen. Psychiatry 63: 210-218.
108. Coviello, D.M. et al A multi-site pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Substance Abuse. In press.
109. Krupitsky, E. et al 2010. Efficacy and safety of extended-release injectable naltrexone (XR-NTX) for the treatment of opioid dependence. Paper presented at the annual meeting of the American Psychiatric Association, Boston, MA
110. Oreskovich, M.R. & R.M. Caldeiro 2009. Anesthesiologists recovering from chemical dependency: can they safely return to the operating room Mayo Clin. Proc. 84: 576-580.
111. Fishman, M.J. et al In press. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: Preliminary case series and feasibility. Addiction.
112. Wise, R.A. & M.A. Bozarth 1987. A psychomotor stimulant theory of addiction. Psychol. Rev. 94: 469-492.
113. Wise, R.A. & P.P. Rompre 1989. Brain dopamine and reward. Annu. Rev. Psychol. 40: 191-225.
114. Jayaram-Lindstrom, N. et al 2004. Effects of naltrexone on the subjective response to amphetamine in healthy volunteers. J. Clin. Psychopharmacol. 24: 665-669.
115. Jayaram-Lindstrom, N.el al. 2008. Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology 33: 1856-1863.
116. Jayaram-Lindstrom, N. et al 2008. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am. J. Psychiatry 165: 1442-1448.
117. Todtenkopf, M.S. et al 2009. Route of administration affects the ability of naltrexone to reduce amphetamine-potentiated brain stimulation reward in rats. Addict. Biol. 14: 408-418.
118. Volpicelli, J.R. et al 2001. Combining medication and psychosocial treatments for addictions: the BRENDA approach. Guilford Press, New York, NY
119. Mercer, D.E. & G.E. Woody 1999. Therapy manuals for drug addiction series. Individual Drug Counseling. National Institutes of Health; US Department of Health and Human Services, Rockville, MD
120. Crits-Christoph, P. et al 1999. Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch. Gen. Psychiatry 56: 493-502.
121. Pettinati, H.M. et al 2004. COMBINE monograph series, volume 2. Medical management treatment manual: a clinical research guide for medically trained clinicians providing pharmacotherapy as part of the treatment for alcohol dependence. DHHS Publication No. (NIH) 04-5289. Bethesda, MD
122. ®) with an employment-based contingency management intervention. Presented at the College on Problems of Drug Dependence, Scottsdale, AZ
123. Fuller, B.E. et al 2005. Adoption of naltrexone to treat alcohol dependence. J. Subst. Abuse Treat. 28: 273-280.
124. Cisler, R.A. et al 2010. Impact of treatment with intramuscular injectable extended-release naltrexone on counseling and support group participation in patients with alcohol dependence. J. Addic. Med. 4: 181-185.
125. McCann, D.J. 2008. Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders. Clin. Pharmacol Ther. 83: 627-630.